Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management

Overview

Journal CNS Neurol Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Neurology
Pharmacology

Date 2024 Jul 29

PMID 39069797

Authors

Amit Anand

Aman Shrivastava

Kuldeep Singh

Rakesh Barik

Devshree Gayakwad

S Jailani

Jailani S

Shamim

Sumeet Dwivedi

Affiliations

Soon will be listed here.

Abstract

Central Nervous System (CNS) disorders affect millions of people worldwide, with a significant proportion experiencing drug-resistant forms where conventional medications fail to provide adequate seizure control. This abstract delves into recent advancements and innovative therapies aimed at addressing the complex challenge of CNS-related drug-resistant epilepsy (DRE) management. The idea of precision medicine has opened up new avenues for epilepsy treatment. Herbs such as curcumin, ginkgo biloba, panax ginseng, bacopa monnieri, ashwagandha, and rhodiola rosea influence the BDNF pathway through various mechanisms. These include the activation of CREB, inhibition of NF-κB, modulation of neurotransmitters, reduction of oxidative stress, and anti- inflammatory effects. By promoting BDNF expression and activity, these herbs support neuroplasticity, cognitive function, and overall neuronal health. Novel antiepileptic drugs (AEDs) with distinct mechanisms of action demonstrate efficacy in refractory cases where traditional medications falter. Additionally, repurposing existing drugs for antiepileptic purposes presents a cost-effective strategy to broaden therapeutic choices. Cannabidiol (CBD), derived from cannabis herbs, has garnered attention for its anticonvulsant properties, offering a potential adjunctive therapy for refractory seizures. In conclusion, recent advances and innovative therapies represent a multifaceted approach to managing drug-resistant epilepsy. Leveraging precision medicine, neurostimulation technologies, novel pharmaceuticals, and complementary therapies, clinicians can optimize treatment outcomes and improve the life expectancy of patients living with refractory seizures. Genetic testing and biomarker identification now allow for personalized therapeutic approaches tailored to individual patient profiles. Utilizing next-generation sequencing techniques, researchers have elucidated genetic mutations.

References

Afra P, Adamolekun B, Aydemir S, Watson G . Evolution of the Vagus Nerve Stimulation (VNS) Therapy System Technology for Drug-Resistant Epilepsy. Front Med Technol. 2022; 3:696543. PMC: 8757869. DOI: 10.3389/fmedt.2021.696543. View

Alachkar A, Lazewska D, Latacz G, Frank A, Siwek A, Lubelska A . Studies on Anticonvulsant Effects of Novel Histamine H3R Antagonists in Electrically and Chemically Induced Seizures in Rats. Int J Mol Sci. 2018; 19(11). PMC: 6274786. DOI: 10.3390/ijms19113386. View

Alnamer R, Alaoui K, Bouidida E, Benjouad A, Cherrah Y . Corrigendum to "Sedative and Hypnotic Activities of the Methanolic and Aqueous Extracts of from Morocco". Adv Pharmacol Pharm Sci. 2020; 2020:5695093. PMC: 7701209. DOI: 10.1155/2020/5695093. View

Anand P, Carlos Othon G, Sakadi F, Tassiou N, Djibo Hamani A, Bah A . Epilepsy and traditional healers in the Republic of Guinea: A mixed methods study. Epilepsy Behav. 2019; 92:276-282. PMC: 6433505. DOI: 10.1016/j.yebeh.2019.01.017. View

Anderson R, Frye M, Abulseoud O, Lee K, McGillivray J, Berk M . Deep brain stimulation for treatment-resistant depression: efficacy, safety and mechanisms of action. Neurosci Biobehav Rev. 2012; 36(8):1920-33. DOI: 10.1016/j.neubiorev.2012.06.001. View

Annegers J . Epidemiology and genetics of epilepsy. Neurol Clin. 1994; 12(1):15-29. View

Anuradha H, Srikumar B, Rao B, Lakshmana M . Euphorbia hirta reverses chronic stress-induced anxiety and mediates its action through the GABA(A) receptor benzodiazepine receptor-Cl(-) channel complex. J Neural Transm (Vienna). 2007; 115(1):35-42. DOI: 10.1007/s00702-007-0821-6. View

Awad R, Levac D, Cybulska P, Merali Z, Trudeau V, Arnason J . Effects of traditionally used anxiolytic botanicals on enzymes of the gamma-aminobutyric acid (GABA) system. Can J Physiol Pharmacol. 2007; 85(9):933-42. DOI: 10.1139/Y07-083. View

Banerjee P, Filippi D, Hauser W . The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009; 85(1):31-45. PMC: 2696575. DOI: 10.1016/j.eplepsyres.2009.03.003. View

10.

Baran S, Brown P, Baudy A, Fitzpatrick S, Frantz C, Fullerton A . Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX. 2022; 39(2):297–314. DOI: 10.14573/altex.2112203. View

11.

Bartsch T, Wulff P . The hippocampus in aging and disease: From plasticity to vulnerability. Neuroscience. 2015; 309:1-16. DOI: 10.1016/j.neuroscience.2015.07.084. View

12.

Bauer S, Baier H, Baumgartner C, Bohlmann K, Fauser S, Graf W . Transcutaneous Vagus Nerve Stimulation (tVNS) for Treatment of Drug-Resistant Epilepsy: A Randomized, Double-Blind Clinical Trial (cMPsE02). Brain Stimul. 2016; 9(3):356-363. DOI: 10.1016/j.brs.2015.11.003. View

13.

Beghi E . The Epidemiology of Epilepsy. Neuroepidemiology. 2019; 54(2):185-191. DOI: 10.1159/000503831. View

14.

Benabid A . Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol. 2003; 13(6):696-706. DOI: 10.1016/j.conb.2003.11.001. View

15.

Benarroch E . GABAA receptor heterogeneity, function, and implications for epilepsy. Neurology. 2007; 68(8):612-4. DOI: 10.1212/01.wnl.0000255669.83468.dd. View

16.

Ben-Menachem E, French J . VNS Therapy versus the latest antiepileptic drug. Epileptic Disord. 2005; 7 Suppl 1:S22-6. View

17.

Berenyi A, Belluscio M, Mao D, Buzsaki G . Closed-loop control of epilepsy by transcranial electrical stimulation. Science. 2012; 337(6095):735-7. PMC: 4908579. DOI: 10.1126/science.1223154. View

18.

Berg A, Testa F, Levy S, Shinnar S . The epidemiology of epilepsy. Past, present, and future. Neurol Clin. 1996; 14(2):383-98. DOI: 10.1016/s0733-8619(05)70263-2. View

19.

Bergey G, Morrell M, Mizrahi E, Goldman A, King-Stephens D, Nair D . Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology. 2015; 84(8):810-7. PMC: 4339127. DOI: 10.1212/WNL.0000000000001280. View

20.

Boison D . Cell and gene therapies for refractory epilepsy. Curr Neuropharmacol. 2008; 5(2):115-25. PMC: 2435346. DOI: 10.2174/157015907780866938. View